curriculum vitae

CURRICULUM VITAE
SERGIO HARARI , M.D.
Milan, March 24th, 2015
Place and date of birth:
Milan (Italy), July 29th, 1960
Address:
Division of Pulmonary Diseases
Ospedale San Giuseppe
Via San Vittore 12
20123 Milan, Italy
T. + 39 02 85994580
Fax +39 02 85994400
E mail: [email protected];
[email protected]
Education:
1985
Medical Degree, University of Milan, Milan (Italy).
1988
Respiratory Diseases Specialist; Italian equivalent of CCST, University of Milan,
Milan (Italy).
1993
Chemotherapy Specialist; Italian equivalent of CCST, University of Milan, Milan
(Italy).
2
1997
Anaesthesiology and Intensive Care Specialist; Italian equivalent of CCST,
University of Milan, Milan (Italy).
2001
Certificate of Expert in Health Care Management - Lombardia Region, Italy.
Employments:
October 2014 - Director ad interim Division of Internal Medicine “Ospedale San Giuseppe”
Milan, Italy
June 2013 -
Chief Department of Medicine, “Ospedale San Giuseppe”
Milan, Italy
1999 -
Director Division of Pulmonary Diseases, Intensive Respiratory Care Unit Pulmonary Function and Hemodynamic Laboratory - “Ospedale San
Giuseppe” Milan, Italy
1989 – 1999
Consultant Respiratory Physician, Department of Chest Diseases, “Ospedale
Niguarda”, Milan, Italy
1991 –1999
Medical Director Lung Transplant Program, “Ospedale Niguarda” , Milan,
Italy
International Clinical and Research Fellowships:
2010
February
Visiting Professor, Harvard Medical School, Massachusetts
General Hospital and Brigham and Women Hospital, U.S.A
Lecture: "Hormonal therapy and Lam expert weigh-in".
2004
May
Visiting Professor, NIH Bethesda U.S.A
Lecture: “An Italian experience in the management of
Lymphangioleiomyomatosis”.
2000
December
Visiting Professor, Centre Chirurgical Marie Lannelongue
(Dir. Prof. Dartevelle). Université Paris Sud, Paris France.
Lecture: “Diagnosis and therapy of Interstitial Lung
Diseases”.
1994
March
Visiting Fellow, Centre Chirurgical Marie Lannelongue
(Dir. Prof. Dartevelle).
Université Paris Sud, Paris France.
– 2–
3
1992
December
Visiting Fellow, Service de Pneumologie et Reanimation
Hospital A. Beclere (Dir. Prof. P. Duroux - Prof. Simonneau)
Université Paris Sud, Paris France.
1992
May
Visiting Fellow, Barnes Hospital, Washington University
(Dir. Prof. J. Cooper) St. Louis, Missouri U.S.A.
1992
April
Visiting Fellow University of Pittsburgh (Medical Dir. Prof.
I. Paradis) Pittsburgh U.S.A.
1991
June- Sept.
Visiting Fellow, Service de Pneumologie et Reanimation
Hopital A. Beclere (Dir. Prof. P. Duroux- Prof. Simonneau)
Université Paris Sud, Paris France.
1990
June-Sept.
Visiting Fellow Centre Chirurgical Marie Lannelongue
(Dir. Prof. Ph. Dartevelle) Université Paris Sud, France.
Academic Assignments
2005 -
Honorary Senior Lecturer for the Medical School of the University of Milan,
Milan Italy. Course.
2008 -
Honorary Senior Lecturer for the Specialist Training in Respiratory Diseases,
University of Milan Bicocca, Milan.
2001-2010
Honorary Senior Lecturer for the Specialist Training in Chest Surgery.
University of Padova, Padova. Italy. Course: Respiratory Diseases: medical
aspects in the management of a lung transplant Patient.
2002-2003
Honorary Senior Lecturer for the Specialist Training in Respiratory Diseases, II
University of Naples, Italy.
Scientific fields of interest:
Rare pulmonary parenchymal and vascular disease
Advance respiratory failure
Pulmonary involvement in systemic diseases (i.e. rheumatological diseases).
Current Editorial Board Activities
Member of the Editorial Board of European Respiratory Review (since 2008), European
Respiratory Journal (since 2013), Sarcoidosis Vasculitis and Diffuse Lung Diseases
(Associate editor since 2008), Geriatric and Medical Intelligence ( since 2010).
– 3–
4
In the last years he served as referee for the following peer reviewed journals :
American Journal of Respiratory and Critical Care Medicine
European Respiratory Journal
European Respiratory Review
European Journal of Internal Medicine
Sarcoidosis Vasculitis and Diffuse Lung Diseases
International Journal of Heart and Lung Transplantation
Respiratory Medicine
PLOS one
Pulmonary Medicine
Orphanet Journal
Clinica Epidemiology
Member of the European board of accreditation in Pneumology
Involved in the evaluation and revision of the scientific literature of the Mc Master University
PLUS/PIER/EB Journals
Current memberships of national and international societies
American Thoracic Society (ATS)
European Respiratory Society (ERS)
Associazione Italiana Pneumologi Ospedalieri(AIPO)
Associazione Italiana Cardiologi Ospedalieri (ANMCO)
Patients Associations
Currently member of the scientific board of the following patients associations:
LAM Italia onlus
Associazione Sclerosi Tuberosa onlus AST
Associazione Italiana lotta alla sclerodermia AILS
– 4–
5
Main international meetings organized:
1.
Lung Transplantation, Milan 1990
2.
Work Shop Italy-France: Pulmonary Thromboembolism. Milan 1992
3.
International Symposium: Pulmonary Hypertension In The Indication Of The HeartLung Transplantation. Milan 1993
4.
Pulmonary Infections In Organ Transplantation
International Congress Milan, 1997
5.
Aspergillus infections in immunocompromised patients: New Insights on Diagnosis
and Treatment. Milan, 2000
6.
New Advances in The Medical Treatment And Management of Primary and
Secondary Pulmonary Hypertension. Milan 2000
7.
First Ripid International Congress: Rare Pulmonary Diseases and Orphan Drugs In
Respiratory Medicine. Milan, 2005
8.
Second Ripid International Congress: Rare Pulmonary Diseases and Orphan Drugs In
Respiratory Medicine. Milan, 2007
9.
Third International Congress on Pulmonary Rare Diseases and Orphan Drugs In
Respiratory Medicine. Milan, 2009
10.
4th International Meeting on Pulmonary Rare Diseases and Orphan Drugs. Milan, 2013
11.
5th International Meeting on Pulmonary Rare Diseases and Orphan Drugs. Milan, 2013
12
6th International Meeting on Pulmonary Rare Diseases and Orphan Drugs. Milan, 2015
He has also organized several (more than 40) national meetings, courses, congresses.
He is frequently invited to speak at national and international scientific meetings ( more than
250 presentations in the last 10 years).
Language skills
Italian: mother tongue
French: mother tongue
English: fluent
Spanish: basic level
– 5–
6
Pubblications
73 publications in PubMed ( 30 in the last 5 years, of these 8 on the ERR)
H-index: 26
Citations last five years 1639
Other
From 2014 he developed a traslational research program on rare pulmonary diseases in
collaboration with the Institute of basic science and non profit foundation INGM ( Istituto
Nazionale di Genetica Molecolare director Prof. Sergio Abrignani).
From 2006 he is a columnist of the most important Italian newspaper, the “Corriere della
Sera”; he writes about scientific topics, public health policy, social issues.
Since 2004 he has developed a collaboration with the NIH ( director dr. Joel Moss) on LAM
with several papers published.
References:
Prof. M. Humbert Editor in chief European Respiratory Journal
Prof. V. Cottin Editor in chief European Respiratory Review
SELECTED PAPERS
01) Role of CMV pneumonia in the development of obliterative bronchiolitis after heartlung and double lung transplantation. J. CERRINA, F. LE ROY LADURIE, PH.
HERVE, F. PARQUIN, S. HARARI, A. CHAPELIER, G. SIMONEAU, P. VOUHE,
PH. DARTEVELLE TRANSPLANTATION INTERNATIONAL 1992; S242-245
02) Early infections and bronchiolitis obliterans-organizing pneumonia in single lung
recipients. letter to the Editor. M. BARBERIS, D. BAUER, S. HARARI, P.A.
BELLONI, T. MASINI, A. BAISI. THE JOURNAL OF HEART AND LUNG
TRANSPLANTATION VOL.11 N. 5 1012-1014, SEPTEMBER 1992
03) Proliferating cell nuclear antigen immunostaining of the endothelial cells in lung
transplantation M. BARBERIS AND S. HARARI TRANSPLANTATION
PROCEEDINGS, VOL 24, N.6 (DEC.), 2667-2669; 1992
04) Recurrence of primary disease in a single lung transplant recipient M. BARBERIS, S.
HARARI, A. TIRONI AND P. LAMPERTICO TRANSPLANTATION
PROCEEDINGS, VOL 24, N.6 DEC.7, 2660-62; 1992
– 6–
7
05) Selection and evaluation of recipients for heart and lung: the niguarda hospital
experience S. HARARI, G. ZIGLIO, F. IOLI, E. DE JULI, C.F. DONNER, E.
GRONDA, E. MICALLEF, M. RAVINI, S. SCOCCIA MONALDI ARCH CHEST DIS
1994; 49,131-7
06) Unusually high plasma CEA values in a patient with idiopathic pulmonary fibrosis S.
HARARI, M. COSTANTINI, P. GHIO, S. SCOCCIA LETTER TO THE EDITOR
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS VOL 9 N° 3 PPL 50,
1994
07) Immunocytochemical detection of progesterone receptors. a study in a patient with
primary pulmonary hypertension M. BARBERIS, S. VERONESE, D. BAUER, E. DE
JULI AND S. HARARI CHEST 1995; 107, 869-74.
08) Rejection and non rejection relate forms of bronchiolitis obliterans: morphological terms
or clinico-pathological entities? M. BARBERIS, S. HARARI, M. BRAMERIO, E.
MINOLA, E. BONACINA and M. GAMBACORTA TRANSPLANTATION
PROCEEDINGS VOL 27, 3 (JUNE) 1995: 2004-5
09) Relapsing aspergillus bronchitis in a double lung transplant patient, succesfully treated
with a new oral antimycotic agent S. HARARI, G.F. SCHIRALDI, E. DE JULI, E.
GRONDA CHEST 1997; 111: 835-836
10) Prognostic value of pulmonary hypertension in patients with chronic interstitial lung
disease referred for lung or heart-lung transplantation S. HARARI, G. SIMMONEAU,
E. DE JULI, F. BRENOT, J. CERRINA, P. COLOMBO, E. GRONDA, E. MICALLEF,
F. PARENT, P. DARTEVELLE JOURNAL OF HEART AND LUNG
TRANSPLANTATION 1997; 16 (4): 460-463
11) Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension
S. HARARI, F. BRENOT, M. BARBERIS, G. SIMMONEAU CHEST, APRIL 1997;
111:1142-44
12) Absence of hyperhomocystinemia in ten patients with primary pulmonary hypertension
M.L. ZIGHETTI, M. CATTANEO, C.R. FALCON, R. LOMBARDI, S. HARARI, S.
SAVONITTO, P.M. MANNUCCI THROMBOSIS RESEARCH 1997; 85, 3 : 279-82
13) Current strategies in the treatment of invasive aspergillus infections
immunocompromise patients S. HARARI DRUGS 1999 OCT; 58 (4) 621-31
in
14) Ear and nose involvement in systemic diseases S. HARARI, G. PACIOCCO, S.
ARAMU MONALDI ARCH CHEST DIS 2000; 55 : 6, 466-470
15) First Report of the Italian Register for diffuse lung disorders C. AGOSTINI, C.
ALBERA, F. BARIFFI, M. DE PALMA, S. HARARI, M. LUSUARDI, A. PESCI, V.
POLETTI, L. RICHELDI, GF. RIZZATO, A. ROSSI, M. SCHIAVINA, G.
SEMENZATO, C. TINELLI MONALDI ARCH CHEST DIS 2001; 56 : 4, 364-8
16) Pulmonary Langerhans’ cell Histiocytosis S. HARARI, A. COMEL SARCOIDOSIS
VASCULITIDIS AND DIFFUSE LUNG DISEASES 2001; 18 : 253-62
– 7–
8
17) Airway inflammation in severe chronic obstructive pumonary disease. Relationship with
lung function and radiological emphysema
TURATO,R.ZUIN,M.MINIATI,S.BARALDO,F.REA,B.BEGHE’,S.MONTI,B.FORMI
CHI,P.BOSCHETTO, S. HARARI, A.PAPI,P.MAESTRELLI,L.M.FABBRI AND
M.SAETTA. AJRCCM 166, PP105-110, 2002
18) Diffuse cystic lung diseases: correlation between radiological and functional status. G.
PACIOCCO, A. BIANCHI, S. HARARI, E. USLENGHI, G. MAZZARELLA, G.
ROVIARO, G. C. VECCHI CHEST 2004;125:135-142.
19) Early pulmonary infections after orthotopic liver transplantation. DE GASPERI, O.
AMICI, G. FANTINI, A. CORTI, E. MAZZA, S. HARARI , M. PROSPERI, P.
NOTARO, E. ROSELLI, M. MARCHESI ACTA ANAESTH. ITALICA 55, 234-254,
2004
20) Idiopathic Pulmonary Fibrosis. CAMINATI, S. HARARI ALLERGY, APRIL 2005, 60 (
4 ) 421-35
21) Does lobectomy for lung cancer in patient with chronic obsrtuctive pulmonary disease
affect lung function ? A Multicenter National Study. BALDI S., RUFFINI E., S.
HARARI , ROVIARO GC., NOSOTTI M., BELLAVITI N., VENUTA F., DIDO D.,
REA F., SCHIRALDI C., DURIGATO A., RAVANELLO M., CARRETTA A.,
TANNINI P. J THORAC CARDIOVASC SURG. 2005; 130(6):1616-22.
22) An integrated clinical approach to diffuse cystic lung diseases G. PACIOCCO, S.
HARARI SARCOIDOSIS VASC DIFFUSE LUNG DIS 2005; 22:S31-S39
23) Which prognostic indicator should we use for clinical practice in the initial evaluation
and Follow-Up of IIP: Should We Depend On Pft, Hrct, Or……. What? A.CAMINATI,
S. HARARI SARCOIDOSIS VASC DIFFUSE LUNG DIS 2005; 22 :S24-S30
24) New frontiers for rare pulmonary diseases. S. HARARI, C. AGOSTINI SARCOIDOSIS
VASC DIFFUSE LUNG DIS 2005; 22:S1-S3
25) Smoking-Related Interstitial Pneumonias and Pulmonary Langerhans Cell Histiocytosis
A.CAMINATI, S. HARARI PROC AM THORAC SOC. 2006 JUN; 3( 4 ): 299-306.
REVIEW.
26) Pulmonary arterial hypertension secondary to chronic lung diseases: pathogenesis and
medical treatment R. CASSANDRO, S. HARARI SARCOIDOSIS VASCULITIS AND
DIFFUSE LUNG DISEASES 2006; 23; 1-17.
27) Effect of a gonadotrophin-releasing hormone analogue on lung function in
Lymphangioleiomyomatosis S. HARARI, R. CASSANDRO, J. CHIODINI, A. M.
TAVEIRA-DASILVA, J. MOSS CHEST. 2008 FEB;133(2):448-54.
28) Walking distance on 6-Mwt is a prognostic factor in Idiophatic Pulmonary Fibrosis
CAMINATI, A. BIANCHI, R. CASSANDRO, MR MIRENDA,S.HARARI,
RESPIRATORY MEDICINE ( 2008 ) XX, 1-7 SUP 9.
– 8–
9
29) Formoterol mono and combination therapy with tiotropium in patients with copd: a 6
months study C. VOGELMEIER, S. HARARI, K. FONAY, J. BEIER, T. OVEREND,
D. TILL, S. S TRENGLEIN, V. OLDANI RESPIRATORY MEDICINE 2008
NOV;102(11):1511-20.
30) Exercise-Induced cardiac costraint by the lungs. A.BIANCHI, S. HARARI, R.
CASSANDRO, P. AGOSTANI INTERNATIONAL JOURNAL OF CARDIOLOGY
31) Evolution of Emphysema in relation to smoking. BELLOMI M, RAMPINELLI C,
VERONESI G, S.HARARI, LANFRANCHI F, RAIMONDI S, MAISONNEUVE P.
EUR RADIOL. 2010 FEB;20(2):286-92. EPUB 2009 AUG 25
32) Routine surgical videothoracoscopy as the first step of the planned resection for lung
cancer. VERGANI C, VAROLI F, DESPINI L, S. HARARI, MOZZI E, ROVIARO G. J
THORAC CARDIOVASC SURG. 2009 NOV;138(5):1206-12.
33) Reversible airflow obstruction in Lymphangioleiomyomatosis. TAVEIRA-DASILVA
AM, STEAGALL WK, RABEL A, HATHAWAY O, S.HARARI, CASSANDRO R,
STYLIANOU M, MOSS J. CHEST DEC. 2009, 136: 1596-1603
34) The histology of pulmonary sarcoidosis: a review with particular emphasis on unusual
and under recognized features. CAVAZZA A, S. HARARI, CAMINATI A,
BARBARESCHI M, CARBONELLI C, SPAGGIARI L, PACI M, ROSSI G. INT J
SURG PATHOL. 2009 JUN;17(3):219-30.
35) Bosentan for patients with chronic thromboembolic Pulmonary Hypertension.
VASSALLO FG, KODRIC M, SCARDUELLI C, S. HARARI, POTENA A, SCARDA
A, PIATTELLA M, CASSANDRO R, CONFALONIERI M. EUR J INTERN MED.
2009 JAN;20(1):24-9
36) The diagnosis of Cystic Lung Diseases: a role for Bronchoalveolar Lavage And
Transbronchial Biopsy ? TORRE O, HARARI S. RESPIR MED. 2010 JUL;104 SUPPL
1:S81-5. EPUB 2010 APR 28.
37) The international lam registry: a component of an innovative web-based clinician,
researcher, and patient-driven rare disease research platform. NUROK M, ESLICK I,
CARVALHO CR, COSTABEL U, D'ARMIENTO J, GLANVILLE AR, HARARI S,
HENSKE EP, INOUE Y, JOHNSON SR, LACRONIQUE J, LAZOR R, MOSS J,
RUOSS SJ, RYU JH, SEYAMA K, WATZ H, XU KF, HOHMANN EL, MOSS F.
LYMPHAT RES BIOL. 2010 MAR;8(1):81-7.
38) IPF: new insight on pathogenesis and treatment. HARARI S, CAMINATI A.
ALLERGY. 2010 MAY;65(5):537-53. EPUB 2010 FEB 1.
39) European Respiratory Society Guidelines for the diagnosis and management of
Lymphangioleiomyomatosis. JOHNSON SR, CORDIER JF, LAZOR R, COTTIN V,
COSTABEL U, HARARI S, REYNAUD-GAUBERT M, BOEHLER A, BRAUNER M,
POPPER H, BONETTI F, KINGSWOOD C; REVIEW PANEL OF THE ERS LAM
TASK FORCE. EUR RESPIR J. 2010 JAN;35(1):14-26.
– 9–
10
40) Evolution of Emphysema in relation to smoking. BELLOMI M, RAMPINELLI C,
VERONESI G, HARARI S, LANFRANCHI F, RAIMONDI S, MAISONNEUVE P.
EUR RADIOL. 2010 FEB;20(2):286-92.
41) Lung function predicts lung cancer risk in smokers: a tool for targeting screening
programmes. CALABRÒ E, RANDI G, LA VECCHIA C, SVERZELLATI N,
MARCHIANÒ A, VILLANI M, ZOMPATORI M, CASSANDRO R, HARARI S,
PASTORINO U. EUR RESPIR J. 2010 JAN;35(1):146-51.
42) Thoracic-Abdominal Mdct: A One-Stop-Shop procedure for diagnosis of
Lymphangioleiomyomatosis N. SVERZELLATI A, P. SPAGNOLO B, S. HARARI C,
M. DE FILIPPO A, M. ZOMPATORI D, C. ROSSI A RESPIRATORY MEDICINE
CME ( 2010 ) 218-219
43) Update on diffuse Parenchymal Lung Disease. HARARI S, CAMINATI A. EUR
RESPIR REV. 2010 JUN 1;19(116):97-108.
44) IPF: New Insight In Diagnosis And Prognosis. CAMINATI A, HARARI S. RESPIR
MED. 2010 JUL;104 SUPPL 1:S2-10. EPUB 2010 JUN 8.
45) The diagnosis of cystic lung diseases: a role for bronchoalveolar lavage and
transbronchial biopsy? TORRE O, HARARI S. RESPIR MED. 2010 JUL;104 SUPPL
1:S81-5. EPUB 2010 APR 28.
46) Rare Pulmonary Diseases: a path to the future. HARARI S, AGOSTINI C. RESPIR
MED. 2010 JUL;104 SUPPL 1:S1. EPUB 2010 APR 28.
47) Pleural and pulmonary involvement in systemic lupus erythematosus. O. TORRE, S.
HARARI PRESSE MED. 2011 JAN;40(1 PT 2):E19-29. EPUB 2010 DEC 30.
REVIEW.
48) A 69-year old female with multiple, bilateral pulmonary nodules CAMINATI, A.
CAVAZZA, MR MIRENDA, S. HARARI EUR RESPIR REV 2011; 20:56-59.
49) Pirfenidone in patients with Idiopathic Pulmonary Fibrosis (Capacity): Two
Randomised Trials. NOBLE PW, ALBERA C, BRADFORD WZ, COSTABEL U,
GLASSBERG MK, KARDATZKE D, KING TE JR, LANCASTER L, SAHN SA,
SZWARCBERG J, VALEYRE D, DU BOIS RM; CAPACITY STUDY GROUP.
LANCET. 2011 MAY 21;377(9779):1760-9. EPUB 2011 MAY 13
50) Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals
with ct screen-detected lung nodules. VERONESI G, SZABO E, DECENSI A,
GUERRIERI-GONZAGA A, BELLOMI M, RADICE D, FERRETTI S, PELOSI G,
LAZZERONI M, SERRANO D, LIPPMAN SM, SPAGGIARI L, NARDI-PANTOLI A,
HARARI S, VARRICCHIO C, BONANNI B. CANCER PREV RES (PHILA). 2011
JAN;4(1):34-42. EPUB 2010 DEC 16
– 10 –
11
51) Lymphangioleiomyomatosis: what do we know and what are we looking for? S.
HARARI , O.TORRE, J. MOSS EUR RESPIR REV. 2011 MAR;20(119):34-44.
REVIEW.
52) Pulmonary Hypertension in Lymphangioleiomyomatosis: Characteristics in 20 patients.
COTTIN V, HARARI S, HUMBERT M, MAL H, DORFMÜLLER P, JAIS X,
REYNAUD-GAUBERT M, PREVOT G, LAZOR R, TAILLÉ C, LACRONIQUE J,
ZEGHMAR S, SIMONNEAU G, CORDIER JF; THE GROUPE D'ETUDES ET DE
RECHERCHE SUR LES MALADIES "ORPHELINES" PULMONAIRES
(GERM"O"P). EUR RESPIR J. 2012 FEB 23.
53) Bronchoscopic
diagnosis
of
Langerhans
Cell
Histiocytosis
and
Lymphangioleiomyomatosis. HARARI S, TORRE O, CASSANDRO R, TAVEIRADASILVA AM, MOSS J. RESPIR MED. 2012 JUL 6.
54) Out-Of-Proportion Pulmonary Hypertention : A paradigm for rare deseases. S.
HARARI CHEST, VOLUME 142 ; P. 1087-1088 ; ISSN : 0012-3692, DOI : DOI :
10.1378/CHEST. 12-1330, 2012.
55) An integrated approach in the diagnosis of smoking-related interstitial lung diseases.
CAMINATI A, CAVAZZA A, SVERZELLATI N, S.HARARI.EUROPEAN
RESPIRATORY
REVIEW, VOL. 21 ; P. 207-2017, INSS :0905-9180, 2012.
56) Global effort against rare and orphan diseases S. HARARI, V. COTTIN, M.
HUMBERT VOL. 21, P. 196-222, 2012
57) Mortality as a primary end-point in ipf treatment trials: the best is the enemy of the
good. WELLS AU, BEHR J, COSTABEL U, COTTIN V, POLETTI V, RICHELDI L.
COLLABORATORS (45) ALBERA C, ANCOCHEA J, ANTONIOU K, BONELLA F,
BONNIAUD P, BOUROS D, BRESSER P, CORDIER J, CRESTANI B,
DOMAGALA-KULAWIK J, DRENT M, EGAN J, GEISER T, GRUNEWALD J,
GRUTTERS J, GUDMUNDSSON G, GUENTHER A, HARARI S., HARRISON N,
HIRANI N, HODGSON U, KAEHLER C, KEANE M, KNEUSSL M, MAHER T,
MOGULKOC N, MULLER-QUERNHEIM J, NEUROHR C, NUNES H, PARFREY H,
PEROS-GOLUBICIC T, POLYCHRONOPOULOS V, PREVOT G, RENZONI E,
ROBALO CORDEIRA C, SALTINI C, SKOLD M, SPAGNOLO P, THOMEER M,
TOMASSETI S, VALEYRE D, VANCHERI C, WALLAERT B, WUYTS W,
XAUBET A. THORAX, VOL. 67; P. 938-940, ISSN: 0040-6376, 2012
58) Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, Randomized
Trial. RAGHU G, BEHR J, BROWN KK, EGAN JJ, KAWUT SM, FLAHERTY KR,
MARTINEZ FJ, NATHAN SD, WELLS AU, COLLARD HR, COSTABEL U,
RICHELDI L, DE ANDRADE J, KHALIL N, MORRISON LD, LEDERER DJ, SHAO
L, LI X, PEDERSEN PS, MONTGOMERY AB, CHIEN JW, O'RIORDAN TG;
ARTEMIS-IPF INVESTIGATORS. ANN INTERN MED. 2013 MAY 7;158(9):641-9.
59) Hypocomplementemic urticarial vasculitis (huvs) with precocious emphysema
responsive to azathioprine. BREDA L, NOZZI M, HARARI S, DEL TORTO M,
LUCANTONI M, SCARDAPANE A, CHIARELLI F. J CLIN IMMUNOL. 2013
– 11 –
12
JUL;33(5):891-5. DOI: 10.1007/S10875-013-9886-1. EPUB 2013 APR 25. NO
ABSTRACT AVAILABLE.
60) Pulmonary hypertension associated with chronic obstructive lung disease and idiopathic
pulmonary fibrosis.
ADIR Y, HARARI S. CURR OPIN PULM MED. 2014 SEP;20(5):414-20.
61)Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. RICHELDI L,
DUBOIS RM, RAGHU G, AZUMA A, BROWN KK, COSTABEL U, COTTIN V,
FLAHERTY KR, HANSELL DM, INOUE Y, KIM DS, KOLB M, NICHOLSON AG,
NOBLE PW, SELMAN M, TANIGUCHI H, BRUN M, LE MAULF F, GIRARD M,
STOWASSER S, SCHLENKER-HERCEG R, DISSE B, COLLARD HR; INPULSIS
TRIAL INVESTIGATORS.
N ENGL J MED. 2014 MAY 29;370(22):2071-82. DOI: 10.1056/NEJMOA1402584.
EPUB 2014 MAY 18. PMID:
62)Reconciling healthcare professional and patient perspectives in the development of
disease activity and response criteria in connective tissue disease-related interstitial lung
diseases. SAKETKOO LA, MITTOO S, FRANKEL S, LESAGE D, SARVER C,
PHILLIPS K, STRAND V, MATTESON EL; OMERACT CONNECTIVE TISSUE
DISEASE–INTERSTITIAL LUNG DISEASES WORKING GROUP; OMERACT
CONNECTIVE TISSUE DISEASE-INTERSTITIAL LUNG DISEASES WORKING
GROUP. J RHEUMATOL. 2014 APR;41(4):792-8. DOI: 10.3899/JRHEUM.131251.
EPUB 2014 FEB 1. PMID:
63)Connective tissue disease related interstitial lung diseases and idiopathic pulmonary
fibrosis: provisional core sets of domains and instruments for use in clinical trials.
SAKETKOO LA, MITTOO S, HUSCHER D, KHANNA D, DELLARIPA PF,
DISTLER O, FLAHERTY KR, FRANKEL S, ODDIS CV, DENTON CP, FISCHER A,
KOWAL-BIELECKA OM, LESAGE D, MERKEL PA, PHILLIPS K, PITTROW D,
SWIGRIS J, ANTONIOU K, BAUGHMAN RP, CASTELINO FV, CHRISTMANN RB,
CHRISTOPHER-STINE L, COLLARD HR, COTTIN V, DANOFF S, HIGHLAND KB,
HUMMERS L, SHAH AA, KIM DS, LYNCH DA, MILLER FW, PROUDMAN SM,
RICHELDI L, RYU JH, SANDORFI N, SARVER C, WELLS AU, STRAND V,
MATTESON EL, BROWN KK, SEIBOLD JR; CTD-ILD SPECIAL INTEREST
GROUP.THORAX. 2014 MAY;69(5):428-36. DOI: 10.1136/THORAXJNL-2013204202. EPUB 2013 DEC 24. ERRATUM IN: THORAX. 2014 SEP;69(9):834. CTDILD SPECIAL INTEREST GROUP [ADDED]; MULTIPLE INVESTIGATOR NAMES
ADDED. PMID:
64)Future perspectives on rare pulmonary diseases and rare presentations of common
disorders.
HARARI S, HUMBERT M, COTTIN V. EUR RESPIR REV. 2013 SEP 1;22(129):199201. DOI: 10.1183/09059180.00004613. NO ABSTRACT AVAILABLE. PMID:
65)Riociguat for the treatment of pulmonary arterial hypertension.
GHOFRANI HA, GALIÈ N, GRIMMINGER F, GRÜNIG E, HUMBERT M, JING ZC,
KEOGH AM, LANGLEBEN D, KILAMA MO, FRITSCH A, NEUSER D, RUBIN LJ;
PATENT-1 STUDY GROUP. N ENGL J MED. 2013 JUL 25;369(4):330-40. DOI:
10.1056/NEJMOA1209655. PMID:
– 12 –
13
66)Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled
MUSIC trial. RAGHU G, MILLION-ROUSSEAU R, MORGANTI A, PERCHENET L,
BEHR J; MUSIC STUDY GROUP. EUR RESPIR J. 2013 DEC;42(6):1622-32. DOI:
10.1183/09031936.00104612. EPUB 2013 MAY 16. PMID:
67) Future perspectives on rare pulmonary diseases and rare presentations of common
disorders.
HARARI S, HUMBERT M, COTTIN V.
EUR RESPIR REV. 2013 SEP 1;22(129):199-201. DOI: 10.1183/09059180.00004613
68)Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized
trial.
RAGHU G, BEHR J, BROWN KK, EGAN JJ, KAWUT SM, FLAHERTY KR,
MARTINEZ FJ, NATHAN SD, WELLS AU, COLLARD HR, COSTABEL U,
RICHELDI L, DE ANDRADE J, KHALIL N, MORRISON LD, LEDERER DJ, SHAO
L, LI X, PEDERSEN PS, MONTGOMERY AB, CHIEN JW, O'RIORDAN TG;
ARTEMIS-IPF INVESTIGATORS*. ANN INTERN MED. 2013 MAY 7;158(9):641-9.
DOI: 10.7326/0003-4819-158-9-201305070-00003. ERRATUM IN: ANN INTERN
MED. 2014 MAY 6;160(9):658
69)Pulmonary hypertension associated with chronic obstructive lung disease and idiopathic
pulmonary fibrosis.
ADIR Y, HARARI S.
CURR
OPIN
PULM
MED.
2014
SEP;20(5):414-20.
DOI:
10.1097/MCP.0000000000000084.
70)Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases.
ALIBERTI S, MESSINESI G, GAMBERINI S, MAGGIOLINI S, VISCA D,
GALAVOTTI V, GIULIANI F,
COSENTINI R, BRAMBILLA AM, BLASI F, SCALA R, CARONE M, LUISI
F, HARARI S, VOZA A,
ESQUINAS A, PESCI A.
BMC PULM MED. 2014 DEC 5;14:194. DOI: 10.1186/1471-2466-14-194
71)Pulmonary hypertension in idiopathic pulmonary fibrosis does not influence six-minute
walk distance: results from a retrospective study.
HARARI S, CAMINATI A, CASSANDRO R, CONTI S, MADOTTO F, LUISI F,
CESANA G.
SARCOIDOSIS VASC DIFFUSE LUNG DIS. 2015 JAN 5;31(4):297-305
72)Rare (pulmonary) disease day: "feeding the breath, energy for life!".
HARARI S, LAU EM, TAMURA Y, COTTIN V, SIMONNEAU G, HUMBERT M.
EUR RESPIR J. 2015 FEB;45(2):297-300. DOI: 10.1183/09031936.00221914.
73)Cellular interactions in the pathogenesis of interstitial lung diseases.
G. BAGNATO AND S. HARARI
EUR RESPIR REV 2015; 24: 102–114 DOI: 10.1183/09059180.00003214.
– 13 –
14
SELECTED PROCEEDINGS, BOOK CHAPTERS AND BOOKS
1)
Utilisation Des Thrombolytiques Dans Le Traitment De L'embolie Pulmonaire
R. AZARIAN, S. HARARI, G. SIMONNEAU
IN: ENCYCLOPEDIE MEDICO-CHIRURGICAL (PARIS) 11-914-A-10, 1994
2)
Interstiziopatie Polmonari
E. DE JULI, S. HARARI, S. SCOCCIA
L.A. SCURO TRATTATO DI MEDICINA INTERNA - FISIOPATOLOGIA E
CLINICA
EDIZIONI UTET 1996; 1921-1940
3)
Il Trapianto Polmonare E Cardiopolmonare
S. HARARI, E. DE JULI, S. SCOCCIA
L.A. SCURO TRATTATO DI MEDICINA INTERNA - FISIOPATOLOGIA E
CLINICA
EDIZIONI UTET 1996; 2165-2178
4)
Terapia Farmacologica nei Trapianti Polmonari
S. HARARI E P.A. BELLONI
F. BERTI, GF. FOLCO, D. OLIVIERI:
DELL'APPARATO RESPIRATORIO
EDIZIONI UTET 1998; 163-169
FARMACOLOGIA
E
TERAPIA
7) Criteri Di Selezione E Gestione Pre-Operatoria Del Candidato A Trapianto Polmonare O
Cardio-Polmonare, Portatore Di Ipertensione Polmonare Primitiva
S. HARARI, E. DE JULI
PROGRESSI CLINICI: MEDICINA VOL. 10 N° 3 PICCIN EDITORE
8) Fibrosi Polmonari Idiopatiche
S. HARARI, A. COMEL
TRATTATO ITALIANO DI PNEUMOLOGIA – VOL. 2 TOMO I PP 1173-1196, 1998
9) Istocitosi Polmonare E Cellule Di Langerhans
S. HARARI, A. COMEL
TRATTATO ITALIANO DI PNEUMOLOGIA – VOL. II TOMO I – PP 1383-1392,
1998
10) Sarcoidosis Vasculitis And Diffuse Lung Diseases. Rare Pulmonary Diseases And
Orphan Drugs In Respiratory Medicine First Ripid International Congres
S. HARARI, C. AGOSTINI ( a cura di )
VOL. 22 SUPPL 1, P. S1-S102, 2005
11) Langerhans’ Cell Histiocytosis
A.CAMINATI, S. HARARI
ENCICLOPEDIA OF REPIRATORY MEDICINE T.E.KING 2006 ELSEVIER PP.
207-212
– 14 –
15
12) Pulmonary Langerhans’ Cell Histiocytosis
A.CAMINATI, S. HARARI
V. COSTABEL, R. DU BOIS, J. EGAN : DIFFUSE PARENCHYMAL LUNG
DISEASE
PROG RESPIR RES. BASEL, KARGER, 2007, VOL. 36 PP. 1-11.
13) Pulmonary Langerhans’ Cell Histiocytosis
HARARI S., CAMINATI A.
EUR RESPIR MON 2009;46: 155-75.
14) Proceedings of The Third International Congress On Rare Diseases And Orphan Drugs
S. HARARI, C. AGOSTINI ( a cura di )
RESPIRATORY MEDICINE VOL. 104 SUPPL 1, P. S1-S91, 2010
15) Book Review: Drug Induced and Iatrogenic Respiratory Diseases
S. HARARI
EUROPEAN REVIEW, VOL. 20 ; P. 214-214, ISSN :0905-9180, 2011
16) Il Medico In Tasca
S. HARARI
BUR-RIZZOLI 2012 p. 1-295
17) Pulmonary Langerhans’ cell histiocytosis
HARARI S, TORRE O, KING TEJR, MOSS J. CHAPTER 61 FISHERMAN’S
PULMONARY DISEASE GRIPPI M, ELIAS J, FISHMAN J, KOTLOFF R, PACK A,
SENIOR R, EDS. FISHMAN’S PULMONARY DISEASES AND DISORDERS, 5TH
ED. NEW YORK: MCGRAW-HILL, IN PRESS.
– 15 –